Originally published as JCO Early Release 10.1200/JCO.2004.11.024 on June 15 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herr, H. W. Articles by Crawford, E. D. Search for Related Content PubMed PubMed Citation Articles by Herr, H. W. Articles by Crawford, E. D. Related Articles Related Article Related Editorials Related Comments and Controversies Social Bookmarking                            What's this?

Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report

From the Memorial Sloan-Kettering Cancer Center, New York, NY; Southwest Oncology Group Statistical Center, Seattle, WA; University of Texas M.D. Anderson Cancer Center, Houston; University of Texas, San Antonio, TX; Salick Health Care, Los Angeles; University of California, Davis, CA; University of Colorado, Denver, CO

Address reprint requests to Southwest Oncology Group (SWOG-8710), Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217; e-mail: bgranados{at}swog.org

PURPOSE: A randomized, cooperative group trial (Southwest Oncology Group 8710, Intergroup 0080) reported that neoadjuvant chemotherapy improved the survival of patients with locally advanced bladder cancer who were treated with radical cystectomy. We evaluated whether surgical factors from patients enrolled onto the study predicted bladder cancer outcomes.

PATIENTS AND METHODS: Surgical and tumor factors were recorded from surgical and pathologic reports from 268 patients with muscle-invasive bladder cancer who received radical cystectomy. Cystectomies were performed by 106 surgeons in 109 institutions. Half of the patients received neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy. Variables were tested in univariate and multivariate analyses for associations with postcystectomy survival (PCS) and local recurrence (LR) in all patients receiving cystectomy.

RESULTS: Five-year PCS and LR rates were 54% and 15%, respectively. A multivariate model adjusted for MVAC (P = .97), age (P = .03), pathologic stage (P = .0002), and node status (P = .04) showed that surgical variables associated with longer PCS were negative margins (v positive; hazard ratio [HR], 0.37; P = .0007), and 10 nodes removed (v < 10; HR, 0.51; P = .0001). These associations did not differ by treatment arms (P > .21 for all tests of interactions between treatment and surgical variables). Predictors of LR in a multivariate model adjusted for MVAC (P = .16), pathologic stage (P = .02), and node status (P = .37) were positive margins (v negative; odds ratio [OR], 11.2; P = .0001) and fewer than 10 nodes removed (v 10; OR, 5.1; P = .002).

CONCLUSION: Surgical factors influence bladder cancer outcomes after cystectomy, after adjustment for pathologic factors and neoadjuvant chemotherapy usage.

Supported in part by the following Public Health Service Cooperative Agreement grants awarded by the National Cancer Institute, Bethesda, MD: CA32102, CA38926, and CA42777.

Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, June 2, 2003, Chicago, IL.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

• Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501
  Takeshi Sano, Mitsuru Sasako, Seiichiro Yamamoto, Atsushi Nashimoto, Akira Kurita, Masahiro Hiratsuka, Toshimasa Tsujinaka, Taira Kinoshita, Kuniyoshi Arai, Yoshitaka Yamamura, and Kunio Okajima
  JCO 2004 22: 2767-2773 [Abstract] [Full Text]

Related Editorials

• Lymphadenectomy for Gastric Cancer
  Paul F. Mansfield
  JCO 2004 22: 2759-2761 [Full Text]
• Does the Who and How of Surgery in Bladder Cancer Matter?
  Paul H. Lange and Daniel W. Lin
  JCO 2004 22: 2762-2764 [Full Text]

Related Comments and Controversies

• Understanding Surgeon Performance and Improving Patient Outcomes
  John D. Birkmeyer
  JCO 2004 22: 2765-2766 [Full Text]

This article has been cited by other articles:

				S. Shirotake, E. Kikuchi, K. Matsumoto, S. Yazawa, T. Kosaka, A. Miyajima, K. Nakagawa, and M. Oya Role of Pelvic Lymph Node Dissection in Lymph Node-Negative Patients with Invasive Bladder Cancer Jpn. J. Clin. Oncol., November 3, 2009; (2009) hyp147v1. [Abstract] [Full Text] [PDF]

				J. W.F. Catto, M. F. Abbod, D. A. Linkens, S. Larre, D. J. Rosario, and F. C. Hamdy Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder Clin. Cancer Res., May 1, 2009; 15(9): 3150 - 3155. [Abstract] [Full Text] [PDF]

				J. E. Rosenberg and W. C. Hahn Bladder cancer: modeling and translation Genes & Dev., March 15, 2009; 23(6): 655 - 659. [Abstract] [Full Text] [PDF]

				R. Thurairaja, U. E. Studer, and F. C. Burkhard Indications, Extent, and Benefits of Pelvic Lymph Node Dissection for Patients with Bladder and Prostate Cancer Oncologist, January 1, 2009; 14(1): 40 - 51. [Abstract] [Full Text] [PDF]

				C. Sweeney, D. F. Bajorin, and C. N. Sternberg Muscle-invasive Bladder Cancer: What Have We Learned and What's New on the Horizon? ASCO Educational Book, January 1, 2008; 2008(1): 200 - 208. [Abstract] [Full Text] [PDF]

				D. J. Parekh, B. H. Bochner, and G. Dalbagni Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments J. Clin. Oncol., December 10, 2006; 24(35): 5519 - 5527. [Abstract] [Full Text] [PDF]

				S. F. Shariat, P. I. Karakiewicz, G. S. Palapattu, G. E. Amiel, Y. Lotan, C. G. Rogers, A. Vazina, P. J. Bastian, A. Gupta, A. I. Sagalowsky, et al. Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. Clin. Cancer Res., November 15, 2006; 12(22): 6663 - 6676. [Abstract] [Full Text] [PDF]

				C. N. Sternberg Are Nomograms Better Than Currently Available Stage Groupings for Bladder Cancer? J. Clin. Oncol., August 20, 2006; 24(24): 3819 - 3820. [Full Text] [PDF]

				S. M. Cohen, A. Goel, J. Phillips, R. D. Ennis, and M. L. Grossbard The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer Oncologist, June 1, 2006; 11(6): 630 - 640. [Abstract] [Full Text] [PDF]

				J. D. Birkmeyer Understanding Surgeon Performance and Improving Patient Outcomes J. Clin. Oncol., July 15, 2004; 22(14): 2765 - 2766. [Full Text] [PDF]

				P. H. Lange and D. W. Lin Does the Who and How of Surgery in Bladder Cancer Matter? J. Clin. Oncol., July 15, 2004; 22(14): 2762 - 2764. [Full Text] [PDF]